A Comparison Between Child-Pugh and Albumin-Bilirubin Scores

May 24, 2018 updated by: Xiaoping Chen, Huazhong University of Science and Technology

A Comparison Between Child-Pugh and Albumin-Bilirubin Scores in Patients With Spontaneous Rupture of Hepatocellular Carcinoma: A Retrospective Study

To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma. And to determine which is better in predicting long-term survival and short-term survival.

Study Type

Observational

Enrollment (Actual)

230

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 76 years (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

From January 2005 to August 2015, all patients complied with the criteria mentioned above who received surgical treatment or non-surgical treatment at the investigator's center were included in this study.

Description

Inclusion Criteria:

  • Be diagnosed as hepatocellular carcinoma pathologically; had a tumor rupture confirmed by Intraperitoneal exploration or clinical signs and symptoms in combination with imaging examination.

Exclusion Criteria:

  • Be diagnosed as not hepatocellular carcinoma pathologically；had repeated transcatheter arterial chemoembolization(TACE) or a long history (more than 1 year) of cancer treatment; loss of follow up or without complete data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Surgical treatment
Patients who received liver resection or palliative surgery, such as microwave coagulation therapy, hepatic artery ligation, or suturing ligation.
Procedure: Liver resection
Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
Non-surgical treatment
Patients who received transcatheter arterial embolization (or transcatheter arterial chemoembolization) or conservative treatment
Other: Transcatheter arterial embolization
Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival of all patients
Time Frame: 5 years
Overall survival of all patients among different Child-Pugh and albumin-bilirubin scores
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Short-term mortality of all patients
Time Frame: Ninety days
Ninety-day mortality of all patients among different Child-Pugh and albumin-bilirubin scores
Ninety days
Short-term mortality of surgical subgroup
Time Frame: Ninety days
Ninety-day mortality of the surgical subgroup among different Child-Pugh and albumin-bilirubin scores
Ninety days
Short-term mortality of non-surgical subgroup
Time Frame: Ninety days
Ninety-day mortality of the non-surgical subgroup among different Child-Pugh and albumin-bilirubin scores
Ninety days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Huazhong University of Science and Technology

Investigators

  • Study Chair: Xiao-ping Chen, Prof. PHD, Huazhong University of Science and Technology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2005

Primary Completion (ACTUAL)

August 1, 2015

Study Completion (ACTUAL)

January 1, 2018

Study Registration Dates

First Submitted

May 12, 2018

First Submitted That Met QC Criteria

May 22, 2018

First Posted (ACTUAL)

May 23, 2018

Study Record Updates

Last Update Posted (ACTUAL)

May 29, 2018

Last Update Submitted That Met QC Criteria

May 24, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Chenxp011

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatocellular Carcinoma

Clinical Trials on Liver resection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe